Ebola and Sudan Virus Vaccines Show Cross-Protection Against Bundibugyo Virus in Preclinical Study
A preclinical study found that vaccines developed against Ebola virus (EBOV) and Sudan virus (SUDV) provided cross-protective immunity against Bundibugyo virus (BDBV) in mouse models. The protection appeared to work through non-neutralizing immune mechanisms rather than antibody neutralization alone. The findings suggest existing ebolavirus vaccines may offer some protection against BDBV, which is currently causing a public health emergency in Central-East Africa.
Researchers developed a surrogate challenge model to test whether existing vaccines against related ebolavirus species could protect against Bundibugyo virus. A yellow fever 17D-vectored BDBV vaccine (YF-BDB) provided complete protection against BDBV challenge in immunocompromised mice. Notably, vaccines targeting EBOV and SUDV also protected mice from BDBV challenge, though the protection was asymmetrical—EBOV and BDBV vaccines only partially protected against SUDV. Serological analysis showed cross-reactive antibodies across vaccine groups, but neutralization capacity was limited, suggesting non-neutralizing immune mechanisms play a major role in protection. The study indicates that SUDV-based antigens may provide broader protection than EBOV or BDBV candidates, and adds preliminary evidence that EBOV vaccines might offer some degree of protection against BDBV during the current outbreak.
What's missing
The study was conducted in mouse models (Ifnar-/- mice), which may not fully translate to human immune responses. The mechanisms underlying non-neutralizing protection are not fully characterized. Clinical efficacy in humans remains to be determined.
What different sources said
- bioRxivCenter
Cross-protection against Bundibugyo by Ebola and Sudan vaccines
Related
Topology-Aware Thermodynamics Improves DNA Probe Specificity Design
Researchers developed a new framework for designing DNA probes that accounts for the spatial organization of matched sequences, not just overall thermodynamic stability. Traditional methods rely on scalar measures like melting temperature and free energy, which miss how mismatches are distributed along the probe. The approach could improve diagnostic accuracy in applications like HPV detection and gene expression profiling.
Study Identifies Optimal Thermal Dose for Combining Focused Ultrasound with Immunotherapy in Tumors
Researchers used multimodal PET imaging to identify an optimal thermal dose range for focused ultrasound ablation that destroys tumor tissue while preserving conditions for immunotherapy delivery. The study found that excessive heating collapses blood vessels needed for antibody access, while insufficient heating fails to adequately reduce tumor burden. The findings could guide clinical design of combination treatments pairing thermal ablation with immunotherapies.
Plant MSH1 Protein Functions as Mismatch-Directed Nuclease for Organelle Genome Maintenance
Researchers have identified the precise mechanism by which the AtMSH1 protein in Arabidopsis plants recognizes and cleaves DNA mismatches and lesions, preventing mutations in organellar genomes. The protein combines a DNA mismatch recognition module with a nuclease domain that makes staggered cuts at specific positions relative to DNA damage. This discovery explains how plants maintain unusually low mutation rates in their mitochondrial and chloroplast DNA compared to other eukaryotes.